Indigenous tetanus and adult diphtheria vaccine launched; Nadda calls it momentous, Pg10

Key Highlights:

• Indigenous tetanus and adult diphtheria (Td) vaccine launched by Union Health Minister J.P. Nadda at Central Research Institute (CRI), Kasauli, Himachal Pradesh.
• CRI to supply 55 lakh doses of the Td vaccine through the Universal Immunization Programme (UIP) by April.
• India recognized as the “pharmacy of the world” and a leading vaccine manufacturer globally.
• India developed two indigenous COVID-19 vaccines within nine months and administered over 220 crore doses.
• CRI is the first government institute to manufacture vaccines under Good Manufacturing Practices (GMP) standards.

Detailed Insights:

• The launch of the indigenously manufactured Td vaccine marks a significant step towards strengthening India’s public health infrastructure and national health security.
• The Universal Immunization Programme (UIP) is the world’s largest immunization program, providing 11 vaccines protecting against 12 vaccine-preventable diseases.
• Development of vaccines and drugs historically took a long time, but India developed COVID-19 vaccines in a short time.
• Good Manufacturing Practices (GMP) standards reflect the modernization of public sector vaccine manufacturing units.

Key Concepts Involved:

• Tetanus and Adult Diphtheria (Td) Vaccine: A vaccine that protects against tetanus and diphtheria, both serious bacterial infections.
• Universal Immunization Programme (UIP): A government program that provides free vaccines against life-threatening diseases to children across the country.
• Good Manufacturing Practices (GMP): A system for ensuring that products are consistently produced and controlled according to quality standards.